Published Constitutional Solution

Medical Cannabis Evidence and Patient Safety Act

Mode: Executive Action Generated by VFA SI Solutions Drafted: 2026.10.04 Published: 2026.10.04

SI-generated · published by a VFA editor on 2026-10-04 · how publication works · Report an error: hello@valuesforamerica.com

Unilateral Presidential action

Increasing Medical Marijuana and Cannabidiol Research

Executive Order

Type
Executive Order
EO number
14370
Signed
2025-12-18
→ View original
VFA SI Solution · Published

Medical Cannabis Evidence and Patient Safety Act

Executive Order 14370 directs completion of an existing marijuana rescheduling rulemaking under federal law, calls for work with Congress on hemp-derived cannabinoid rules, and asks HHS, FDA, CMS, and NIH to develop real-world evidence methods to inform care and patient safety.

Constitutional concerns with the original

  1. Any direction to complete rescheduling must preserve the Controlled Substances Act procedure and must not predetermine the agency decision.
  2. A new research program or binding product standard needs statutory authority and an available congressional appropriation.
  3. Voluntary research and product enforcement need appropriate privacy, notice, and review safeguards while respecting the limits of federal and state authority.

Solution text

Congress would create a five-year, capped research program on medical marijuana and lawful hemp-derived cannabinoids. The program would address the evidence and patient-safety gaps described in Executive Order 14370, while leaving drug scheduling decisions to the existing Controlled Substances Act process. The order itself does not appropriate research money or establish this proposed program. The Attorney General would carry out any still-pending marijuana scheduling rulemaking under 21 U.S.C. 811 in accordance with applicable procedures and the administrative record; this bill would not predetermine the result. Subject to annual appropriations, HHS, FDA, CMS, and NIH would coordinate voluntary clinical and real-world evidence studies of potential benefits, adverse events, drug interactions, dosing, and longer-term outcomes. Study protocols, conflicts of interest, and aggregate results would be public. Participation would be voluntary, with informed consent and protection of patient data, especially for older adults and younger populations. FDA and HHS would assess the safety, composition, and labeling of lawful hemp-derived cannabinoid products under their existing authorities and report to Congress on any statutory authority still needed. Any new binding product standard beyond current authority would require legislation. The program would neither approve a treatment by implication nor create access to an unapproved product. It would preserve existing state law except where a valid federal law expressly provides otherwise. Congress would authorize no more than $50 million per year for five years, subject to a separate annual appropriation. This is a proposed, uncosted ceiling, not spending in Executive Order 14370. HHS would report annually to Congress on grants, study methods, adverse-event reporting, spending, and evidence limits; GAO would assess the program before the fifth year. The new grant authority would expire after five years unless renewed. Grant enforcement would include notice and an opportunity to contest repayment, while existing administrative and judicial review rights would remain intact.

Operative provisions

funding source
Proposed annual congressional appropriations to HHS; no funding is supplied by Executive Order 14370.
funding amount
Proposed authorization ceiling of $50 million annually for five years ($250 million maximum), subject to appropriations; no fiscal score or offset has been verified.
sunset years
5
oversight body
HHS annual public reporting to Congress; proposed GAO evaluation before renewal.
enforcement mechanism
Proposed grant agreement audits and recovery of misused funds after notice and an opportunity to contest; existing agency authorities govern scheduling and product enforcement.
judicial review path
Existing applicable review rights remain; this proposal creates no new private cause of action.

Source basis and limits

Basis: Checked Federal Register document 2025-23846, Executive Order 14370, published December 23, 2025 (90 FR 60541-60543), sections 1-3. Section 2(a) directs the Attorney General to complete marijuana rescheduling rulemaking in accordance with federal law. Section 2(b) calls for work with Congress on hemp-derived cannabinoids and for HHS, FDA, CMS, and NIH to develop real-world evidence methods under federal law. Section 3 preserves existing agency authority and makes implementation subject to appropriations.

Check before relying on this: The order reports prevalence and FDA findings, but those underlying studies and current rulemaking status were not independently verified here. The five-year grant program, $250 million ceiling, reports, GAO review, and grant remedies are VFA proposals, not provisions or cost estimates in the order. Existing FDA authority, fiscal effects, clinical outcomes, and any final scheduling decision need separate verification before legislation.

Bipartisan rationale

A possible coalition could join members seeking stronger clinical evidence, clearer patient warnings, and reliable product information with members seeking limits on new spending and fidelity to existing federal and state law. The proposal leaves the rescheduling outcome to the statutory process and asks Congress to weigh new research authority and costs. This describes possible interests, not recorded endorsements.

Constitutional citations

  • → Article I, Section 8, Clauses 1, 3, and 18 (proposed congressional research and commerce legislation)
  • → Article I, Section 9, Clause 7 (appropriations)
  • → Article II, Section 3 (execution of existing law)
  • → Fifth Amendment (procedural safeguards where applicable)
  • → Tenth Amendment (limits of federal and state authority)

Article I, Section 8 Article I, Section 9, Clause 7 Article II, Section 3 Amendment V Amendment X

Possible legislative path

Congressional committees with jurisdiction over health, the Controlled Substances Act, and appropriations could hold hearings on research design, FDA authority, state-law interaction, and a CBO cost estimate. No member support or vote margin has been verified.

Report an error in this Solution
No account needed. Or email hello@valuesforamerica.com. How reports are handled.

Share card

Download share card Square (1080×1080) Preview

1200×675 PNG for X, Threads, LinkedIn and messages. Free to share with a link back to this page.

Citizen Consensus

“Do you support this VFA SI Solution?”

One vote per verified account; you can change it any time. Only verified accounts count, results publish once 30 verified people have voted, and state and district results count only people who attested a home ZIP code. How this works.

Email verification is not switched on yet, so no vote counts toward results yet. Votes cast now are saved and count once the voter verifies their email address.

Sign in or create a free account to vote.

Add a short reason (optional)

/280 · no links or contact details · reasons are reviewed before anyone sees them, and many never are shown.

Your vote is saved but held out of published results by an automated integrity check (for example, several accounts voting from one browser).

Your vote is saved. It will count once you verify your email address. Verify on your account page.

Your vote counts nationally. Add your home ZIP code to count in your state and district too.

Your vote counts nationally and in .

Reason saved privately; it is shown only if it passes review.

A sudden surge of votes on this item was flagged and is under review; votes from new accounts in that surge are held out until it is resolved.

National, state and district results →

Related on VFA

Generated by VFA SI Solutions · 2026.10.04 03:06 UTC · ← Back to the Republic